(0.04%) 5 471.75 points
(0.07%) 39 141 points
(0.29%) 17 769 points
(-0.24%) $80.64
(-5.04%) $2.62
(-0.89%) $2 310.10
(-0.37%) $28.76
(3.07%) $1 016.70
(0.33%) $0.936
(0.74%) $10.68
(0.50%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors...
Stats | |
---|---|
Dagens volum | 3.29M |
Gjennomsnittsvolum | 3.85M |
Markedsverdi | 1.33B |
EPS | $-0.230 ( Q3 | 2023-11-13 ) |
Neste inntjeningsdato | ( $0 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
11.36 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.322 (2.58%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-26 | Goodman Jonathan R. | Sell | 41 872 | Common Stock |
2023-12-27 | Goodman Jonathan R. | Sell | 35 872 | Stock Option (Right to Buy) |
2023-12-27 | Goodman Jonathan R. | Sell | 25 000 | Stock Option (Right to Buy) |
2023-12-27 | Goodman Jonathan R. | Sell | 25 614 | Stock Option (Right to Buy) |
2023-12-27 | Goodman Jonathan R. | Sell | 44 749 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-79.61 |
Last 96 transactions |
Buy: 3 517 450 | Sell: 10 366 533 |
Volum Korrelasjon
POINT Biopharma Global Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
LVOX | 0.847 |
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
POINT Biopharma Global Korrelasjon - Valuta/Råvare
POINT Biopharma Global Økonomi
Annual | 2022 |
Omsetning: | $226.58M |
Bruttogevinst: | $226.58M (100.00 %) |
EPS: | $1.040 |
FY | 2022 |
Omsetning: | $226.58M |
Bruttogevinst: | $226.58M (100.00 %) |
EPS: | $1.040 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-1.181 |
FY | 2020 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-0.00801 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
POINT Biopharma Global
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.